Angiopoietin-2 specific TIE2 receptor
AssigneeUnited Kingdom Research and Innovation
InventorsNicolas Phillip James Brindle, Julian Edward Sale
Life of this patent
Estimating the term…
Abstract
In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided.
Claims6
A polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the fragment comprises a sequence corresponding to residues 23-210 of SEQ ID NO:
- 1, wherein the polypeptide binds preferentially to angiopoietin-2 (Ang2) compared to angiopoeitin-1 (Ang1);
- wherein the angiopoietin receptor is Tie2, and wherein the polypeptide comprises the following mutations with respect to SEQ ID NO:
- 1 or SEQ ID NO:
- 2:
- (i) F161I, ΔR167 and ΔH168, or
- (ii) F161G, ΔR167 and ΔH168.
A polypeptide that binds preferentially to angiopoietin-2 compared to angiopoietin-1, said polypeptide comprising the amino acid sequence of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.